The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first GLP-1 receptor agonist tablet for weight loss and weight management, marking a significant milestone in obesity treatment. The drug, semaglutide, sold under the brand name Wegovy, is now available in pill form, offering a convenient alternative to weekly injections.
Approval Details
On 11 June 2026, the MHRA granted approval for the semaglutide tablet, which contains the same active ingredient as the injectable version. This approval makes the UK the first country to authorize a GLP-1 tablet for weight management, potentially transforming how patients approach weight loss therapy.
Who Can Use the Tablet?
The tablet is approved for adults with obesity, defined as a Body Mass Index (BMI) of 30 or above. It may also be prescribed to overweight individuals with a BMI between 27 and 30 who have at least one weight-related health condition, such as type 2 diabetes or high blood pressure. As with the injectable version, the tablet is not a standalone solution; it must be combined with a reduced-calorie diet and increased physical activity.
Dosing Schedule
The treatment follows a gradual dose escalation to allow the body to adjust. The starting dose is 1.5 mg once daily, which increases to 4 mg, then 9 mg, and finally to the maximum dose of 25 mg. Each dose level must be maintained for at least one month before stepping up. This slow titration helps minimize side effects and ensures tolerability.
Transitioning from Injections
For patients already using the 2.4 mg semaglutide injection once weekly, the MHRA has confirmed a direct transition to the 25 mg daily tablet is possible without repeating the lower doses. This streamlined switch applies to those receiving the injection privately, offering a practical and welcome alternative to needles.
Broader Implications
This approval signals a shift in weight management treatment, making it more accessible and less invasive. While the NHS has not yet announced widespread availability, the regulatory approval opens the door for future adoption. The tablet's convenience could encourage more people to seek treatment, potentially reducing the burden of obesity-related diseases.
The semaglutide tablet represents a new chapter in obesity care, combining proven efficacy with a user-friendly format. As the UK leads this innovation, other regulators worldwide may follow suit, expanding options for millions struggling with weight management.
